$HOWL News

Here's Why We're A Bit Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Situation

Werewolf Therapeutics (NASDAQ:HOWL) Meets Q1 Estimates, Clears Debt, and Advances Strategic Review

Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates

Werewolf Therapeutics Q1 EPS $(0.28), Inline

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates

Werewolf Therapeutics Q4 EPS $(0.20) Beats $(0.35) Estimate

Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives

Werewolf Therapeutics shares are trading higher after the company announced plans to explore strategic alternatives.

Werewolf Therapeutics shares are trading higher after the company announced plans to explore strategic alternatives.

Trading Halt: Halt status updated at 4:25:00 PM ET: Quotation Resumption: News and Resumption Times

Werewolf Therapeutics Mulls Strategic Options

Trading Halt: Halted at 4:10:00 p.m. ET - Trading Halt: Halt News Pending

Werewolf Therapeutics Plans To Cut Workforce By 64%, To Record One-Time Charge In Q1 Of ~$4.1M; CFO Timothy W. Trost Resigns, Michael Urban Appointed Principal Financial Officer And Principal Accounting Officer

Werewolf Therapeutics (HOWL) Eyes 2026 Catalysts Following FDA Guidance and Encouraging INDUKINE Results

HC Wainwright & Co. Maintains Buy on Werewolf Therapeutics, Lowers Price Target to $4

Werewolf Therapeutics Announces Pipeline and Business Updates

Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know

B of A Securities Maintains Buy on Werewolf Therapeutics, Lowers Price Target to $7

Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

Werewolf Therapeutics Releases Preclinical Data Demonstrating Its Inducer T Cell Engager Platform And Indukine Molecules Show Potent Antitumor Activity With Reduced Systemic Toxicity